{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:41:18Z","timestamp":1779205278897,"version":"3.51.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Due to remarkable progress in cancer treatment, endocrine complications are now the major medical issues facing childhood cancer survivors. Although non-central\u00a0nervous system solid tumors (NCSTs) account for approximately 40% of all pediatric cancers, there have been few studies on endocrine complications associated with NCSTs. This study investigated endocrinopathies following the treatment of pediatric\u00a0NCSTs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>Retrospective study in a single academic center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study analyzed 253 survivors of childhood NCSTs who were diagnosed between January of 2000 and December of 2018. The medical charts were reviewed regarding the frequency of endocrinopathies and treatment modalities. The hazard ratios were assessed by multivariable Cox regression analysis. The final height-SDS were analyzed by multivariable linear regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 76 patients (30%) that developed at least one endocrine complication. Forty-four patients (17.4%) experienced endocrine complications within five years of their cancer diagnosis. The most common endocrine complication was growth failure (n = 35), followed by obesity (n = 18), and primary gonadal failure (n = 16). High cumulative doses of alkylating agents increased the risk of developing at least one endocrine complication. Hematopoietic stem cell transplantation was an important risk factor for primary gonadal failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study described the comprehensive endocrine outcomes, including growth failure, obesity, primary gonadal failure, primary hypothyroidism, dyslipidemia, and osteoporosis, following the treatment of childhood NCSTs. As endocrinopathies occurred within five years of primary tumor diagnosis, surveillance for endocrine dysfunction is required for early intervention and management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.610730","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T12:12:50Z","timestamp":1615983170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Endocrine Complications in Children and Adolescents With Non-Central Nervous System Solid Tumors"],"prefix":"10.3389","volume":"12","author":[{"given":"Yena","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunha","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyery","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Nam","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Joon","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1633","article-title":"Childhood solid tumours: a developmental disorder","volume":"5","author":"Scotting","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.24.2705","article-title":"Medical assessment of adverse health outcomes in long-term survivors of childhood cancer","volume":"297","author":"Geenen","year":"2007","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-1043","article-title":"Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics","volume":"168","author":"Brignardello","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-14-236","article-title":"Final height and body mass index in adult survivors of childhood acute lymphoblastic leukemia treated without cranial radiotherapy: a retrospective longitudinal multicenter Italian study","volume":"14","author":"Bruzzi","year":"2014","journal-title":"BMC Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/17446651.2019.1561271","article-title":"Long-term effects on growth, development, and metabolism of ALL treatment in childhood","volume":"14","author":"Bruzzi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/jco.2014.56.7933","article-title":"Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study","volume":"33","author":"Chemaitilly","year":"2015","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.13.5293","article-title":"Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial","volume":"26","author":"Laughton","year":"2008","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-018-2765-0","article-title":"Long-term endocrine effects and trends in body mass index changes in patients with childhood-onset brain tumors","volume":"138","author":"Seo","year":"2018","journal-title":"J Neurooncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1542\/pir.2017-0057","article-title":"Pediatric solid tumors of infancy: an overview","volume":"39","author":"Allen-Rhoades","year":"2018","journal-title":"Pediatr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0268-960x(02)00042-5","article-title":"Endocrine complications in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Howard","year":"2002","journal-title":"Blood Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5025","article-title":"Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study","volume":"34","author":"Clement","year":"2016","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/08880010903019344","article-title":"Late effects of treatment for wilms tumor","volume":"26","author":"Wright","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq278","article-title":"Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study","volume":"102","author":"Ginsberg","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2015.10.064","article-title":"Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma","volume":"54","author":"Clement","year":"2016","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2018-0273","article-title":"Endocrine consequences of neuroblastoma treatment in children: 20 years\u2019 experience of a single center","volume":"32","author":"Geurten","year":"2019","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000355577","article-title":"Endocrine complications and components of the metabolic syndrome in survivors of childhood malignant non-brain solid tumors","volume":"81","author":"Shalitin","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/78.3.459","article-title":"Leukemia after therapy with alkylating agents for childhood cancer","volume":"78","author":"Tucker","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"B20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/pbc.24679","article-title":"The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study","volume":"61","author":"Green","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2018.61.5.135","article-title":"The 2017 Korean national growth charts for children and adolescents: development, improvement, and prospects","volume":"61","author":"Kim","year":"2018","journal-title":"Korean J Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000111809","article-title":"Endocrine late effects of childhood cancer therapy: a report from the Children\u2019s Oncology Group","volume":"69","author":"Nandagopal","year":"2008","journal-title":"Horm Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apa.12266","article-title":"Early recognition of growth abnormalities permitting early intervention","volume":"102","author":"Haymond","year":"2013","journal-title":"Acta Paediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clinbiochem.2011.10.003","article-title":"Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents","volume":"45","author":"Hyun","year":"2012","journal-title":"Clin Biochem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.pcl.2011.07.009","article-title":"Etiology and treatment of hypogonadism in adolescents","volume":"58","author":"Viswanathan","year":"2011","journal-title":"Pediatr Clin North Am"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jocd.2009.09.006","article-title":"Bone mineral density according to age, bone age, and pubertal stages in Korean children and adolescents","volume":"13","author":"Lim","year":"2010","journal-title":"J Clin Densitom"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-015-0686-y","article-title":"Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex: results of the 2009-2010 Korean National Health and Nutrition Examination Survey (KNHANES)","volume":"34","author":"Kang","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1062-3","article-title":"Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems","volume":"21","author":"Fan","year":"2010","journal-title":"Osteoporos Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0054","article-title":"Diagnosis of endocrine disease: endocrine late-effects of childhood cancer and its treatments","volume":"176","author":"Chemaitilly","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01175","article-title":"Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Sklar","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000493943","article-title":"Childhood Cancer Treatments and Associated Endocrine Late Effects: A Concise Guide for the Pediatric Endocrinologist","volume":"91","author":"Chemaitilly","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds580","article-title":"Final height in survivors of childhood cancer compared with Height Standard Deviation Scores at diagnosis","volume":"24","author":"Knijnenburg","year":"2013","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0180","article-title":"The effect of chemotherapy on the growing skeleton","volume":"26","author":"van Leeuwen","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1989.tb06332.x","article-title":"Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage proteoglycan resorption in-vitro","volume":"41","author":"Rainsford","year":"1989","journal-title":"J Pharm Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1570225","article-title":"Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation","volume":"157","author":"Robson","year":"1998","journal-title":"J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22839","article-title":"Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma","volume":"56","author":"Hobbie","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.2.3576","article-title":"Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats","volume":"6","author":"Xian","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1203\/01.PDR.0000100903.83472.09","article-title":"Bone turnover and growth during and after chemotherapy in children with solid tumors","volume":"55","author":"Bath","year":"2004","journal-title":"Pediatr Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1996.tb14223.x","article-title":"Shortened and diminished pubertal growth in boys and girls treated for acute lymphoblastic leukaemia","volume":"85","author":"Groot-Loonen","year":"1996","journal-title":"Acta Paediatr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08880018709141243","article-title":"Disturbed pubertal growth in girls treated for acute lymphoblastic leukemia","volume":"4","author":"Moell","year":"1987","journal-title":"Pediatr Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4159","article-title":"Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study","volume":"99","author":"Patterson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0112","article-title":"Long-term safety of growth hormone replacement after CNS irradiation","volume":"96","author":"Mackenzie","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.7.8606","article-title":"Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study","volume":"87","author":"Sklar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0656","article-title":"Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor","volume":"91","author":"Ergun-Longmire","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01205","article-title":"GH Therapy in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis","volume":"103","author":"Tamhane","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.12.7044","article-title":"Growth hormone treatment of children with brain tumors and risk of tumor recurrence","volume":"85","author":"Swerdlow","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431304","article-title":"Effect of growth hormone treatment on the adult height of children with chronic renal failure","volume":"343","author":"Haffner","year":"2000","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.06.039","article-title":"The prevalence of overweight and obesity in pediatric survivors of cancer","volume":"149","author":"Nathan","year":"2006","journal-title":"J Pediatr"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3332","article-title":"Obesity in pediatric ALL survivors: a meta-analysis","volume":"133","author":"Zhang","year":"2014","journal-title":"Pediatrics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24703","article-title":"Metabolic syndrome in pediatric cancer survivors: a mechanistic review","volume":"60","author":"Rosen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2010.05.100031","article-title":"Lifetime follow-up care after childhood cancer","volume":"23","author":"Haddy","year":"2010","journal-title":"J Am Board Family Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3390\/nu11123062","article-title":"Metabolic Disturbances in Children Treated for Solid Tumors","volume":"11","author":"Barg","year":"2019","journal-title":"Nutrients"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0020","article-title":"Acute ovarian failure in the childhood cancer survivor study","volume":"91","author":"Chemaitilly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/282147","article-title":"Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells","volume":"2014","author":"Orio","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.218","article-title":"Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems","volume":"49","author":"Cohen","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s0936-6555(89)80039-1","article-title":"Ovarian failure following abdominal irradiation in childhood: natural history and prognosis","volume":"1","author":"Wallace","year":"1989","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.01.023","article-title":"Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children\u2019s Oncology Group Report","volume":"22","author":"Chow","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2011.339","article-title":"Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern","volume":"24","author":"Cho","year":"2011","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.45","article-title":"Late endocrine effects of childhood cancer","volume":"12","author":"Rose","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951101)76:9<1662::aid-cncr2820760924>3.0.co;2-v","article-title":"Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma","volume":"76","author":"Picco","year":"1995","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2013.56.2.60","article-title":"Bone mineral density deficits in childhood cancer survivors: pathophysiology, prevalence, screening, and management","volume":"56","author":"Kang","year":"2013","journal-title":"Korean J Pediatr"},{"key":"B63","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/humupd\/dmr038","article-title":"Long-term endocrine side effects of childhood Hodgkin\u2019s lymphoma treatment: a review","volume":"18","author":"van Dorp","year":"2012","journal-title":"Hum Reprod Update"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000001060","article-title":"Hypovitamininosis D in Childhood Cancer Survivors: Importance of Vitamin D Supplementation and Measurement Over Different Points of Time","volume":"40","author":"Fouda","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/jayao.2016.0023","article-title":"Patterns of Loss to Follow-Up Care Among Childhood Cancer Survivors","volume":"6","author":"Rokitka","year":"2017","journal-title":"J\u00a0Adolesc Young Adult Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.610730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T12:12:53Z","timestamp":1615983173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.610730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":65,"alternative-id":["10.3389\/fendo.2021.610730"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.610730","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"article-number":"610730"}}